Epigenetix is a clinical stage pharma company with a first-in-class oral cancer drug about to begin phase on trials at 5 leading US cancer centers. We will include patients with prostate cancer, pancreatic cancer, breast cancer, sarcoma, NUT carcinoma and other cancers where our drug has shown
unprecedented anti-cancer activity. Our drug was selected among many
other drug candidates to potently inhibit three different validated
cancer drug targets: p300/CBP + BRD4+ CECR2. Treatment
results in elimination of both the tumor itself as well as associated metastases. This powerful drug fights cancer in multiple ways: (1) by eradicating tumor cells directly (cytotoxic therapy), (2) by unleashing the body’s immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy). While presently pursued as monotherapy, synergy with checkpoint inhibitors, PARP inhibitors, CDK4/6 inhibitors as well as epigenetic drugs, such as EZH2 inhibitors ,has been shown preclinically.
Company Details
- Employees
- 7
- Founded
- 2011
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.epigenetix.com
- Keywords
- biomodal.
Epigenetix Questions
Epigenetix's website is http://www.epigenetix.com
Epigenetix's LinkedIn profile is https://www.linkedin.com/company/epigenetix
Epigenetix has
7 employees.
View email and phone details for 7
employees at Epigenetix.
Epigenetix's industry is
Biotechnology Research
Epigenetix's top competitors are
Epigenetiks Genetik Biyoinformatik Yazılım A.ş.,
Iremedy,
Emissary International Llc,
Meda Ventures,
Prodarcsiem,
Epigenetix™,
Biomodal,
Sanofi,
Clinsytes Integrated Clinical Solutions,
Electro-Medic.
Epigenetix's categories are Biotechnology Research
Epigenetix's founding year is 2011
